China’s Sinovac vaccine has ‘general efficacy’ of 50.4% in Brazil trials, says Butantan

A coronavirus vaccine developed by China’s Sinovac showed “general efficacy” of 50.4% in a late-stage trial in Brazil, the company’s local partners said on Tuesday, revealing a more modest figure …
( read original story …)